{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:50:38Z","timestamp":1780642238345,"version":"3.54.1"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Bulevirtide is a first-in-class antiviral drug to treat chronic hepatitis B\/D. We investigated the drug-drug interaction potential and pharmacokinetics of high-dose subcutaneous bulevirtide (5\u00a0mg twice daily) with organic anion transporting polypeptide 1B1 (OATP1B1) and cytochrome P450 (CYP) 3A4.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This was a single-center, open-label, fixed-sequence drug-drug interaction trial in 19 healthy volunteers. Before and at bulevirtide steady state, participants ingested a single 40\u00a0mg dose of pravastatin. A midazolam microdose was applied to quantify CYP3A4 activity.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> At bulevirtide steady state, pravastatin area under the concentration-time curve (AUC<jats:sub>0\u2013\u221e<\/jats:sub>) increased 1.32-fold (90% CI 1.08-1.61). The 5\u00a0mg bulevirtide twice-daily treatment resulted in a mean AUC<jats:sub>0-12<\/jats:sub> of 1210\u00a0h*ng\/ml (95% CI 1040-1408) and remained essentially unchanged under the influence of pravastatin. CYP3A4 activity did not change to a clinically relevant extent. As expected, total bile acids increased substantially (35-fold) compared to baseline during bulevirtide treatment. All study medication was well tolerated.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> The study demonstrated that high-dose bulevirtide inhibited OATP1B-mediated hepatic uptake of the marker substrate pravastatin but the extent is considered clinically not relevant. Changes in CYP3A4 activity were also not clinically relevant. In conclusion, this study suggests that OATP1B substrate drugs as well as CYP3A4 substrates may safely be used without dose adjustment in patients treated with bulevirtide. However, in patients using high statin doses and where concomitant factors potentially further increase statin exposure, caution may be required when using bulevirtide.<\/jats:p>","DOI":"10.3389\/fphar.2023.1128547","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T05:54:05Z","timestamp":1680760445000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers"],"prefix":"10.3389","volume":"14","author":[{"given":"Vanessa","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Czock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter E.","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9461","DOI":"10.3748\/wjg.v21.i32.9461","article-title":"Management of hepatitis delta: Need for novel therapeutic options","volume":"21","author":"Abbas","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00228-011-1065-9","article-title":"Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler\u00ae-based method","volume":"67","author":"Aklillu","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.3748\/wjg.v27.i23.3249","article-title":"Update on the management and treatment of viral hepatitis","volume":"27","author":"Almeida","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/cpt.744","article-title":"The NTCP-inhibitor myrcludex B: Effects on bile acid disposition and tenofovir pharmacokinetics","volume":"103","author":"Blank","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","article-title":"First-in-human application of the novel Hepatitis B and hepatitis D virus entry inhibitor myrcludex B","volume":"65","author":"Blank","year":"2016","journal-title":"J. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3851\/IMP3206","article-title":"Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro","volume":"23","author":"Blank","year":"2017","journal-title":"Antivir. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B - first results of a Phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00216-011-5675-y","article-title":"Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry","volume":"402","author":"Burhenne","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: A systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"key":"B10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3109\/00498254.2010.523736","article-title":"Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors","volume":"41","author":"Choi","year":"2011","journal-title":"Xenobiotica"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.clinthera.2009.06.006","article-title":"Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects","volume":"31","author":"Deng","year":"2009","journal-title":"Clin. Ther."},{"key":"B12","unstructured":"Guideline on bioanalytical method validation2011"},{"key":"B13","unstructured":"Guideline on the investigation of bioequivalence2010"},{"key":"B14","unstructured":"Hepcludex assessment report2020"},{"key":"B15","first-page":"342","article-title":"Current and future management of chronic hepatitis D","volume":"14","author":"Farci","year":"2018","journal-title":"Gastroenterol. Hepatol. (N Y)"},{"key":"B16","unstructured":"Drug development and drug interactions. Table of substrates, inhibitors and inducers2020"},{"key":"B17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genomewide study","volume":"359","author":"Group","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1007\/s00216-015-8853-5","article-title":"Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: Monitoring Hepatitis B therapy by a novel Na(+)-taurocholate cotransporting polypeptide inhibitor","volume":"407","author":"Haag","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.clpt.2003.09.011","article-title":"Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression","volume":"75","author":"Hedman","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/FPC.0b013e3280ef698f","article-title":"Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants","volume":"17","author":"Ho","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","article-title":"Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics","volume":"130","author":"Ho","year":"2006","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1128\/AAC.02347-12","article-title":"Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin","volume":"57","author":"Hulskotte","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.clpt.2006.01.010","article-title":"Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin","volume":"79","author":"Igel","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"B24","first-page":"173","article-title":"Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver","volume":"27","author":"Jacobsen","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","article-title":"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors","volume":"94","author":"Jacobson","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00228-010-0878-2","article-title":"Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam","volume":"66","author":"Katzenmaier","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy","volume":"90","author":"Katzenmaier","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11095-006-9159-2","article-title":"Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans","volume":"24","author":"Kivisto","year":"2007","journal-title":"Pharm. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1586\/ecp.11.58","article-title":"Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions","volume":"4","author":"Koenen","year":"2011","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S0009-9236(03)00052-3","article-title":"Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance","volume":"73","author":"Kyrklund","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","article-title":"Bulevirtide with or without pegIFN\u03b1 for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies","volume":"77","author":"Lampertico","year":"2022","journal-title":"J. Hepatol."},{"key":"B33","first-page":"775","article-title":"The effect of Na+\/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males","volume":"69","author":"Lou","year":"2014","journal-title":"Pharmazie"},{"key":"B34","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3109\/00498254.2015.1130881","article-title":"Mixed effects of OATP1B1, BCRP and NTCP polymorphisms on the population pharmacokinetics of pravastatin in healthy volunteers","volume":"46","author":"Lu","year":"2016","journal-title":"Xenobiotica"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J. Infect. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.2133\/dmpk.dmpk-11-rv-099","article-title":"Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs","volume":"27","author":"Nakanishi","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2165\/00003088-200847070-00003","article-title":"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin","volume":"47","author":"Neuvonen","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0009-9236(98)90165-5","article-title":"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole","volume":"63","author":"Neuvonen","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2217\/14622416.8.7.787","article-title":"Role of OATP transporters in the disposition of drugs","volume":"8","author":"Niemi","year":"2007","journal-title":"Pharmacogenomics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/01.fpc.0000114750.08559.32","article-title":"High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)","volume":"14","author":"Niemi","year":"2004","journal-title":"Pharmacogenetics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","article-title":"Cyclosporin A inhibits Hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor","volume":"60","author":"Nkongolo","year":"2014","journal-title":"J. Hepatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0009-9236(97)90034-5","article-title":"Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses","volume":"62","author":"Olbricht","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.1007\/s00216-021-03384-7","article-title":"Intact plasma quantification of the large therapeutic lipopeptide bulevirtide","volume":"413","author":"Sauter","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1128\/JVI.01902-09","article-title":"Fine mapping of pre-S sequence requirements for Hepatitis B virus large envelope protein-mediated receptor interaction","volume":"84","author":"Schulze","year":"2010","journal-title":"J. Virol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/hep.29251","article-title":"Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice","volume":"66","author":"Slijepcevic","year":"2017","journal-title":"Hepatology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"15924","DOI":"10.3390\/ijms232415924","article-title":"Metabolic effect of blocking sodium-taurocholate Co-transporting polypeptide in hypercholesterolemic humans with a twelve-week course of bulevirtide-an exploratory phase I clinical trial","volume":"23","author":"Stoll","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e0169719","DOI":"10.1371\/journal.pone.0169719","article-title":"Preference of conjugated bile acids over unconjugated bile acids as substrates for OATP1B1 and OATP1B3","volume":"12","author":"Suga","year":"2017","journal-title":"PLoS One"},{"key":"B50","doi-asserted-by":"publisher","first-page":"6262","DOI":"10.3748\/wjg.v20.i20.6262","article-title":"Management of chronic Hepatitis B infection: Current treatment guidelines, challenges, and new developments","volume":"20","author":"Tang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/jps.24214","article-title":"A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation","volume":"104","author":"Thiel","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.tiv.2018.06.018","article-title":"Human OATP1B1 (SLCO1B1) transports sulfated bile acids and bile salts with particular efficiency","volume":"52","author":"Toth","year":"2018","journal-title":"Toxicol Vitro"},{"key":"B53","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1152\/physrev.00027.2002","article-title":"Bile salt transporters: Molecular characterization, function, and regulation","volume":"83","author":"Trauner","year":"2003","journal-title":"Physiol. Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: Virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"key":"B55","unstructured":"Guidance for industry, bioanalytical method validation2018"},{"key":"B56","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1177\/1091581820953066","article-title":"Assessment of statin interactions with the human NTCP transporter using a novel fluorescence assay","volume":"39","author":"Wang","year":"2020","journal-title":"Int. J. Toxicol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/s0168-8278(22)00433-0","article-title":"Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: Week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study","volume":"77","author":"Wedemeyer","year":"","journal-title":"JHepatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with Hepatitis B virus and hepatitis D virus coinfection (MYR202): A multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"","journal-title":"Lancet Infect. Dis."},{"key":"B59","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S0618-8278(19)30141-0","article-title":"Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV\/HDV co-infection","volume":"70","author":"Wedemeyer","year":"2019","journal-title":"Hepatology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/00003088-200241050-00003","article-title":"Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors","volume":"41","author":"Williams","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"B61","unstructured":"Guidelines for the prevention, care and treatment of persons with chronic Hepatitis B infection2015"},{"key":"B62","unstructured":"Hepatitis B fact sheet"},{"key":"B63","unstructured":"Hepatitis D fact sheet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human Hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"elife"},{"key":"B65","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jhep.2022.05.023","article-title":"Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread","volume":"77","author":"Zhang","year":"2022","journal-title":"J. Hepatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1128547\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T05:54:13Z","timestamp":1680760453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1128547\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":65,"alternative-id":["10.3389\/fphar.2023.1128547"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1128547","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]},"article-number":"1128547"}}